You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Government & Policy Articles
Popular Government & Policy Articles
Highly Recommended Government & Policy Articles
Send a link to this page to your friends and colleagues.
On May 8, an advisory panel of the U.S. Food and Drug Administration (FDA) recommended approval of the bioengineered skin substitute Apligraf.
Manufactured by Organogenesis Inc., Apligraf is intended for use in the treatment of diabetic foot ulcers of greater than two weeks duration. Apligraf has already been given FDA clearance for the treatment of venous leg ulcers.
Foot Ulcers Can Lead to Amputation
Between 600,000 and 800,000 people in the United States currently suffer from diabetic foot ulcers. This foot complication is a potential cause of amputation and is the most frequent cause of hospitalization among people with diabetes. Diabetic foot ulcers are estimated to cost the U.S. health care system over $1 billion per year.
56 Percent of Diabetic Foot Ulcers Healed
The Apligraf diabetic ulcer pivotal trial was a large, prospective, randomized, multi-center study. For the study, 208 patients were treated with either Apligraf plus standard care or diabetic ulcer standard care alone.
Use of Apligraf healed 56 percent of ulcers within 12 weeks, compared to 38 percent healing with standard care alone. Use of Apligraf was also found to reduce time of healing. Complete healing was achieved in an average of 65 days with Apligraf, compared to 90 days with standard care alone.
Apligraf plus standard care was not associated with any significant side effects.
For more information, call Organogenesis 781-575-0775
0 comments - Jan 7, 2000
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.